




PATENT
Docket No. 252312006103

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV232305976US

Date of Deposit: April 24, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


Michael Boyd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Edward J. VICTORIA, et al.

Serial No.: 10/044,844

Filing Date: January 10, 2002

For: APL IMMUNOREACTIVE PEPTIDES,
CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL
ANTIBODY-MEDIATED
PATHOLOGIES

Examiner: To Be Assigned

Group Art Unit: 1641

SUBMISSION OF FORMAL DRAWINGS

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed are 32 sheet(s) of formal drawings in connection with the above-identified application.


Respectfully submitted,

Dated: April 24, 2003

By: 

Kimberly A. Bolin
Registration No. 44,546

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5740
Facsimile: (650) 494-0792



1/32

ACA Activity Effect of Serum vs Fish Gelatin




FIG. 1



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Immunoreactivity of ACA 6501-5A12 Peptide




FIG. 2



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATHOLOGIES

Inventor: Edward J. VICTORIA, et al.

Application No.: 10/044,844

Docket No.: 252312006103

Sheet 3 of 32

3/32

Immunoreactivity of ACA-6626 with Solid Phase Peptides




FIG. 3



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 4 of 32

4/32

Serum Crossreactivity of ACA 6501-5A12 Peptide




FIG. 4



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
THOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 5 of 32

5/32

Serum Crossreactivity of ACA 6626-4D3 Peptide





FIG. 5



6/32

ACA ELISA of Serum 6501



CALCULATION FOR GPL UNITS IN SERUM
6501: 1600dil./50 dil. x 70 GPL= 2240 GPL

FIG. 6B

O.D. 550 nm vs. Std. GPL UNITS





FIG. 6A



7/32

ACA ELISA of Purified Ab fr. Serum 6501



From the graph purified 6501 Ab had 70.1GPL in 0.5 ug / ml
or 140.2GPL in 1 ug / ml

FIG. 7



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 8 of 32

8/32




FIG. 8



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDICATED
INVENTOR: EDWARD J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 9 of 32

9/32





FIG. 9



10/32




CLONE #

FIG. 10




11/32

Inhibition of (3B10)4/6501 Derived by 6501
Derived Peptide Monomer with 400 Diluted
Ser.6501



µg PEPTIDE / WELL

FIG. 11



12/32

**Inhibition of Cdl-2.3% Hu Ser.(no IgG) by
Modified Peptides 3G3 with 400x Diluted
Serum 6501**




FIG. 12

13/32

Inhibition of (3B10)4/6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501





FIG. 13




14/32

Inhibition of (3B10)4/6501 Derived by Alpha MeP 3B10
Monomer with 400 Diluted Serum 6501



---□--- 726 = AGMePCLLAPDRCPG = 2.25ug inhibited 50% ser.6501
—■— 727 = AGPCLLAMePDRCPG = 0.125ug inhibited 50% ser.6501
—◇— 728 = AGMePCLLAMePDRCPG = 0.625ug inhibited 50% ser.6501
---◆--- 3B10 = AGPCLLAPDRCPG = 0.5ug inhibited 50% ser.6501
☆ no peptide
● blank
— 50% inhibition

FIG. 14



15/32

Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ β 2-GPI-coated plates




FIG. 15



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIA
PAT. LOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 16 of 32

16/32

LJP 685-MTU-DABA-PEG (COMPOUND 36)




FIG. 16




Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIA PATENT LOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 17 of 32

17/32

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)



CONCENTRATION OF TOLEROGEN IN DISH.
Treatment groups.

FIG. 17



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 18 of 32

18/32




FIG. 18



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
HOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 19 of 32

19/32





FIG. 19



20/32

Amino or other positively charged group

$$D(1,2) = 22^\circ$$



Gem-dimethyl or other small hydrophobic group



FIG. 20A





FIG. 20B

21/32

Inhibition of β_2 GP-1 by 6501-Derived Peptides with 350x Diluted Serum 6501




FIG. 21



22/32

**6701 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻**




FIG. 22



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 23 of 32

23/32

**6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻**




FIG. 23



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PA... LOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 24 of 32

24/32

**6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻**




FIG. 24



25/32

Displacement of CB2*-F from 6701 using 1.04 eq. of CB2*: GPCILLARDRCG-CO₂⁻





FIG. 25



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
DISEASES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 26 of 32

26/32

**CB2* Titration of CB2*-F/6701:
CB2*: GPCILLARDRCG-CO₂⁻**




FIG. 26



27/32

**3B10 Titration of CB2*-F/6701:
3B10: AGPCLLLAPDRCPG-CO₂⁻**




FIG. 27



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 28 of 32

28/32




FIG. 28



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 29 of 32

29/32




FIG. 29



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED
PATHOLOGIES
Inventor: Edward J. VICTORIA, et al.
Application No.: 10/044,844
Docket No.: 252312006103

Sheet 30 of 32

30/32




FIG. 30



31/32




FIG. 31



32/32




FIG. 32